GeneQuantum

Executive Summary

GeneQuantum is a private Chinese biotechnology company advancing next-generation antibody-drug conjugates (ADCs) for oncology. Its proprietary enzymatic site-specific conjugation platforms, iLDC and iGDC, enable precise and stable payload attachment, potentially improving therapeutic index and reducing off-target toxicity. The pipeline targets validated antigens HER2, Trop2, and FGFR3 across multiple solid tumors. Lead candidates are in Phase 2 clinical development, with initial data expected in the near term. The company's differentiated technology and focus on high-value ADC targets position it competitively in the rapidly growing ADC space, though it faces challenges including intense competition and the need to demonstrate clinical superiority.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for HER2-targeting ADC (e.g., GQ-1001)35% success
• Q4 2026Phase 2 data readout for Trop2-targeting ADC (e.g., GQ-1002)30% success
• Q3 2026Initiation of Phase 2 trial for FGFR3-targeting ADC40% success